Eberle, R.Ph., M.B.A. "We've secured volume discounts for our abiraterone product that we are passing along to our members and to patients. This price reduction is proof that our model is working." ...
Triple therapy with darolutamide vs abiraterone for metastatic hormone-sensitive prostate cancer is associated with better clinical outcomes. Triplet therapy that includes darolutamide vs ...
Olaparib plus abiraterone improved survival vs placebo in BRCA-mutated metastatic castration-resistant prostate cancer.
DelveInsight’s, “Metastatic Prostate Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in metastatic prostate cancer pipeline landscape. It ...
Osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration ...
Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Real world comparison of time-to-next-treatment (TTNT), ...
NICE is unable to make a recommendation about the use in the NHS of niraparib (Zejula) with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This ...
CivicaScript,® a nonprofit company dedicated to bringing low-cost generic medicines to U.S. consumers, announced today that it has lowered the price of its lead product, Abiraterone Acetate Tablets, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback